MX2023012460A - Una forma de tafamidis en estado solido y un proceso para su preparacion. - Google Patents

Una forma de tafamidis en estado solido y un proceso para su preparacion.

Info

Publication number
MX2023012460A
MX2023012460A MX2023012460A MX2023012460A MX2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A
Authority
MX
Mexico
Prior art keywords
preparation
tafamidis
solid state
state form
crystalline form
Prior art date
Application number
MX2023012460A
Other languages
English (en)
Spanish (es)
Inventor
Massimo Zampieri
Piero Paravidino
Giuseppe Barreca
Luca Carcone
Daniele Pengo
Liming Huang
Original Assignee
Quim Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quim Sintetica S A filed Critical Quim Sintetica S A
Publication of MX2023012460A publication Critical patent/MX2023012460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
MX2023012460A 2021-04-26 2022-04-22 Una forma de tafamidis en estado solido y un proceso para su preparacion. MX2023012460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382362.8A EP4083027A1 (en) 2021-04-26 2021-04-26 A solid state form of tafamidis and a process for its preparation
PCT/EP2022/060716 WO2022229026A1 (en) 2021-04-26 2022-04-22 A solid state form of tafamidis and a process for its preparation

Publications (1)

Publication Number Publication Date
MX2023012460A true MX2023012460A (es) 2023-12-14

Family

ID=75746555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012460A MX2023012460A (es) 2021-04-26 2022-04-22 Una forma de tafamidis en estado solido y un proceso para su preparacion.

Country Status (8)

Country Link
US (1) US20240208915A1 (cg-RX-API-DMAC10.html)
EP (2) EP4083027A1 (cg-RX-API-DMAC10.html)
JP (1) JP7881608B2 (cg-RX-API-DMAC10.html)
CN (1) CN117255781A (cg-RX-API-DMAC10.html)
BR (1) BR112023022116A2 (cg-RX-API-DMAC10.html)
CA (1) CA3216325A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023012460A (cg-RX-API-DMAC10.html)
WO (1) WO2022229026A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023091534A1 (en) * 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
WO2026159144A1 (en) 2025-01-22 2026-07-30 Inke, S.A. Solid forms of tafamidis methyl ethyl ketone solvate and processes for their manufacture

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
HUE056583T2 (hu) 2014-09-08 2022-02-28 Pfizer 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
HRP20250159T1 (hr) 2019-05-16 2025-03-28 Assia Chemical Industries Ltd. Kruti oblici tafamidisa i njegovih soli
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021019448A1 (en) 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof

Also Published As

Publication number Publication date
CN117255781A (zh) 2023-12-19
BR112023022116A2 (pt) 2024-01-09
JP2024515770A (ja) 2024-04-10
EP4330237A1 (en) 2024-03-06
EP4083027A1 (en) 2022-11-02
CA3216325A1 (en) 2022-11-03
JP7881608B2 (ja) 2026-06-29
WO2022229026A1 (en) 2022-11-03
US20240208915A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
IL318601A (en) Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
AR063710A1 (es) Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
ZA202407964B (en) Processes for preparing ag-10, its intermediates, and salts thereof
WO2012065114A3 (en) Polyketal adducts, methods of manufacture and uses thereof
ZA202311094B (en) Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
WO2021016220A3 (en) Synthesis of substituted furans
SI1601653T1 (sl) Postopek za pripravo substituiranih estrov nikotinske kisline
MX378594B (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos
BR112023022116A2 (pt) Uma forma em estado sólido de tafamidis e um processo para sua preparação
AR116423A1 (es) Un proceso de fabricación de compuestos heterocíclicos de 2-nitroimino
DK1877384T3 (da) Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
MX2025009371A (es) Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello
MX2025014399A (es) Sintesis de acil sulfoximinas ciclicas
EA202192581A1 (ru) Композиции d-метирозина и способы их получения
US3922281A (en) Process for the preparation of 3-(O,O-diethyldithiophosphorylmethyl)-6-chloro-benzoxazolone
MX2024014493A (es) Formas solidas de heterociclilamidas como inhibidores de irak4
SE7907455L (sv) Nytt forfarande for framstellning av vissa cefemforeningar
TW202617700A (zh) 用於製備4-胺基-呋喃之方法
MX2024003962A (es) Procedimiento para preparar compuestos activos tipo sartanes que tienen un anillo de tetrazol.
MX2023010998A (es) Un compuesto de quinolona en formas solidas y procesos para su preparacion.
MX2025000464A (es) Forma cristalina de un esteroide neuroactivo
MX2024007679A (es) Compuestos intermedios cristalinos.
WO2024186788A3 (en) High purity nitric oxide releasing compounds and methods of preparing same